Depression, a chronic debilitating illness of substantial concern, has been estimated to affect >15% of women during menopausal transition. Clinical studies suggest that supplementation with fish oil omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) effectively benefits mood disorders and depression. Moreover, research has linked EPA monotherapy or a higher EPA/DHA ratio with better antidepressive
outcomes than an enriched DHA supplementation. This presentation will discuss the mechanisms of action, application and clinical efficacy of EPA and DHA supplementation in targeting depression, as well as other symptoms associated with menopause, including hot flashes, irregular heartbeat, and joint aches and pains.